Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Huntington disease
Biotech
PTC and Novartis’ Huntington's data fail to convince investors
Investors wiped almost 20% off PTC’s share price amid doubts about the path to accelerated approval of the asset.
Nick Paul Taylor
May 6, 2025 7:25am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Novartis pays PTC $1B upfront for midphase Huntington's program
Dec 2, 2024 7:53am
uniQure's interim data shows gene therapy slows Huntington’s
Jul 9, 2024 9:25am
Sage's dalzanemdor trial design leaves efficacy question unclear
Jun 11, 2024 8:28am
VectorY raises $138M to push forward ALS program
Nov 13, 2023 10:26am
